CytomX Therapeutics (FRA:6C1) Cyclically Adjusted FCF per Share: €-0.57 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6C1 CytomX Therapeutics Inc FRA:6C1
42 GF Score
Price €2.87
GF Value €0.25
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Cyclically Adjusted FCF per Share?

CytomX Therapeutics FRA:6C1 +0.46% 42 Cyclically Adjusted FCF per Share is €-0.57 as of Mar. 2026. GuruFocus rates FRA:6C1 with a GF Score™ of 42/100 and a GF Value™ of €0.25 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

CytomX Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.125. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.57 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-25), CytomX Therapeutics's current stock price is €2.869. CytomX Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.57. CytomX Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


CytomX Therapeutics  (FRA:6C1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


CytomX Therapeutics Cyclically Adjusted FCF per Share Related Terms


CytomX Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Cyclically Adjusted FCF per Share Chart

CytomX Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.73 -0.58

CytomX Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -0.61 -0.62 -0.58 -0.57

FRA:6C1 vs ALLO, XOMA, OCS: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:6C1
42GF Score
CytomX Therapeutics Inc FRA:6C1
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytomX Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.125/330.2130*330.2130
=-0.125

Current CPI (Mar. 2026) = 330.2130.

CytomX Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.379 241.018 0.519
201609 -0.369 241.428 -0.505
201612 0.035 241.432 0.048
201703 -0.513 243.801 -0.695
201706 4.183 244.955 5.639
201709 -0.132 246.819 -0.177
201712 0.479 246.524 0.642
201803 -0.322 249.554 -0.426
201806 -0.604 251.989 -0.791
201809 -0.129 252.439 -0.169
201812 -0.582 251.233 -0.765
201903 -0.801 254.202 -1.041
201906 -0.956 256.143 -1.232
201909 -0.479 256.759 -0.616
201912 -0.598 256.974 -0.768
202003 -0.977 258.115 -1.250
202006 1.871 257.797 2.397
202009 -0.468 260.280 -0.594
202012 -0.315 260.474 -0.399
202103 -0.426 264.877 -0.531
202106 -0.361 271.696 -0.439
202109 -0.391 274.310 -0.471
202112 -0.426 278.802 -0.505
202203 -0.584 287.504 -0.671
202206 -0.500 296.311 -0.557
202209 -0.525 296.808 -0.584
202212 -0.022 296.797 -0.024
202303 0.131 301.836 0.143
202306 -0.356 305.109 -0.385
202309 -0.211 307.789 -0.226
202312 -0.250 306.746 -0.269
202403 -0.291 312.332 -0.308
202406 -0.215 314.175 -0.226
202409 -0.219 315.301 -0.229
202412 -0.223 315.605 -0.233
202503 -0.225 319.799 -0.232
202506 -0.106 322.561 -0.109
202509 -0.080 324.800 -0.081
202512 -0.118 324.054 -0.120
202603 -0.125 330.213 -0.125

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.57 mean?
CytomX Therapeutics (FRA:6C1) has a Cyclically Adjusted FCF per Share of €-0.57 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors.
Is CytomX Therapeutics' Cyclically Adjusted FCF per Share too high?
CytomX Therapeutics' current Cyclically Adjusted FCF per Share is €-0.57. Overall, CytomX Therapeutics has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Cyclically Adjusted FCF per Share compare to ALLO and XOMA?
CytomX Therapeutics' Cyclically Adjusted FCF per Share of €-0.57 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors. CytomX Therapeutics's current Cyclically Adjusted FCF per Share is €-0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (FRA:6C1) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.25, compared to a current price of €2.87 — trading 1047.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.57. CytomX Therapeutics' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For CytomX Therapeutics (FRA:6C1), the current Cyclically Adjusted FCF per Share is €-0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (FRA:6C1) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of €2.87 is trading 1047.6% above its estimated GF Value™ of €0.25. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:6C1:

  • Cyclically Adjusted FCF per Share: €-0.57
  • GF Value™: €0.25 vs. price of €2.87 (1047.6% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the FRA:6C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytomX Therapeutics Business Description

Other Exchanges CTMX:USA6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
42GF Score

Get the complete analysis for FRA:6C1

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.87
Price
€0.25
GF Value